Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
9IP1 Analyst Ratings
Hold
1 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9IP1 Stock 12 Month Forecast
Average Price Target
€5.07
▲(38.23% Upside)
| Highest Price Target€6.76 | Average Price Target€5.07 | Lowest Price Target€4.23 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Hold
―
Initiated
02/26/26
Bank of America Securities
€6.76
Buy
84.30%
Upside
Reiterated
01/15/26
Morgan Stanley
€5.92→€4.23
Hold
15.19%
Upside
Reiterated
01/08/26
Evercore ISI
€4.23
Hold
15.19%
Upside
Reiterated
12/17/25
J.P. Morgan
―
Sell
―
Downgraded
11/18/25
Needham
―
Hold
―
Reiterated
11/07/25
LifeSci Capital
€7.61
Buy
107.34%
Upside
Reiterated
11/07/25
Wedbush
€13.53
Buy
268.61%
Upside
Reiterated
11/07/25
Cantor Fitzgerald
€6.76
Buy
84.30%
Upside
Reiterated
11/06/25
Chardan Capital
€10.15→€9.3
Buy
153.42%
Upside
Reiterated
11/06/25
William Blair
―
Buy
―
Reiterated
11/06/25
Canaccord Genuity
€8.45
Buy
130.38%
Upside
Reiterated
08/20/25
Goldman Sachs
€1.69
Sell
-53.92%
Downside
Reiterated
08/20/25
Jefferies
€2.11→€2.54
Hold
-30.89%
Downside
Reiterated
08/08/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Hold
―
Initiated
02/26/26
Bank of America Securities
€6.76
Buy
84.30%
Upside
Reiterated
01/15/26
Morgan Stanley
€5.92→€4.23
Hold
15.19%
Upside
Reiterated
01/08/26
Evercore ISI
€4.23
Hold
15.19%
Upside
Reiterated
12/17/25
J.P. Morgan
―
Sell
―
Downgraded
11/18/25
Needham
―
Hold
―
Reiterated
11/07/25
LifeSci Capital
€7.61
Buy
107.34%
Upside
Reiterated
11/07/25
Wedbush
€13.53
Buy
268.61%
Upside
Reiterated
11/07/25
Cantor Fitzgerald
€6.76
Buy
84.30%
Upside
Reiterated
11/06/25
Chardan Capital
€10.15→€9.3
Buy
153.42%
Upside
Reiterated
11/06/25
William Blair
―
Buy
―
Reiterated
11/06/25
Canaccord Genuity
€8.45
Buy
130.38%
Upside
Reiterated
08/20/25
Goldman Sachs
€1.69
Sell
-53.92%
Downside
Reiterated
08/20/25
Jefferies
€2.11→€2.54
Hold
-30.89%
Downside
Reiterated
08/08/25
Best Analysts Covering Rocket Pharmaceuticals
3 Months
xxx
Success Rate
15/25 ratings generated profit
Average Return
+13.11%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +13.11% per trade.
1 Year
Success Rate
15/25 ratings generated profit
Average Return
+18.76%
a rating ―
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +18.76% per trade.
2 Years
xxx
Success Rate
4/12 ratings generated profit
Average Return
-17.88%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -17.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9IP1 Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
13
9
8
6
1
Buy
3
2
2
1
0
Hold
14
6
6
3
3
Sell
1
1
1
1
0
Strong Sell
0
0
0
0
0
total
31
18
17
11
4
Each month's total comprises the sum of three months' worth of ratings.
9IP1 Financial Forecast
9IP1 Stock Forecast FAQ
What is DE:9IP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is 5.07.
What is DE:9IP1’s upside potential, based on the analysts’ average price target?
Rocket Pharmaceuticals has 38.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rocket Pharmaceuticals a Buy, Sell or Hold?
Rocket Pharmaceuticals has a consensus rating of Hold, which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.
What is Rocket Pharmaceuticals’s share price target?
The average share price target for Rocket Pharmaceuticals is 5.07. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €6.76 ,and the lowest forecast is €4.23. The average share price target represents 38.23% Increase from the current price of €3.67.
The highest analyst share price target is €6.76 ,and the lowest forecast is €4.23. The average share price target represents 38.23% Increase from the current price of €3.67.
What do analysts say about Rocket Pharmaceuticals?
Rocket Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of Rocket Pharmaceuticals?
To buy shares of DE:9IP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.